| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 98.64 Billion |
| Market Size (2030) | USD 124.70 Billion |
| CAGR (2025 - 2030) | 4.80 % |
| Fastest Growing Market | North America |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
North America Advanced Drug Delivery Systems Market Analysis
The North America Advanced Drug Delivery Systems Market size is estimated at USD 98.64 billion in 2025, and is expected to reach USD 124.70 billion by 2030, at a CAGR of 4.8% during the forecast period (2025-2030).
Advanced drug delivery system is an innovative technology that enables more effective, targeted, and controlled administration of pharmaceutical products, leading to improved therapeutic outcomes. In addition, advanced drug delivery results in increased bioavailability compared to traditional drug delivery systems.
Factors such as the development of new drugs and biologics, advancements in understanding human biology and diseases, and an increase in research and development spending are expected to boost the market’s growth over the forecast period. The increasing burden of chronic diseases requiring advanced drug formulation and enhanced therapeutic outcomes from novel drug delivery systems are further projected to boost market growth over the forecast period.
The increasing development of advanced drug delivery systems to improve bioavailability and overall treatment outcomes is likely to accelerate the market’s growth over the forecast period. For instance, according to an article published by Heliyon in June 2023, drug delivery systems were formulated with advanced technology and microcarrier technology to foster the systemic target delivery of the drug to improve treatment outcomes.
In addition, according to the same source, several new drug delivery approaches, including hyaluronic acid-based drug nanocarriers, drug delivery systems, and self-micro emulsifying drug-delivery systems, were developed to treat several solid tumors and pulmonary infections. Thus, such developments of advanced drug delivery systems to improve the therapeutic bioavailability of treatment are expected to increase the development of advanced drug delivery systems, boosting market growth over the forecast period.
Ongoing efforts to develop novel drug delivery systems for life-threatening conditions such as idiopathic pulmonary fibrosis (IPF) and others to facilitate effective drug delivery is another factor expected to spur market expansion. For instance, according to an article published by AAPS PharmSciTech in April 2024, treatment options for pulmonary fibrosis (IPF) are being formulated with advanced delivery systems such as chitosan nanoparticles, solid lipid nanocarriers, and liposomal-based nanocarriers for effective therapeutic administration of drugs. Thus, such incorporation of advanced drug delivery approaches in drug formulations is likely to increase their uptake, which is expected to boost market growth over the forecast period.
Moreover, companies are focusing on adopting various business strategies, such as new product launches, partnerships, and collaborations, that also contribute to market growth. For instance, in March 2024, HypoSpray Pharma and Nascent Biotech Inc. collaborated to manufacture an alternative delivery mechanism for patients to eliminate bi-weekly weekly infusions in cancer patients.
Similarly, in February 2022, NuGen Medical Devices Inc. delivered a purchase order from a Taiwanese medical distributor, Shin-Ya Biotechnology Co. Ltd, for its InsuJet needleless injection system. This is part of a multi-year sales and distribution contract with a minimum commitment of CDN 100,000 (USD 73,326) during the first two years. Thus, such initiatives are further expected to fuel market growth over the coming years.
Therefore, owing to the aforementioned factors, such as the increasing advancements in biological drugs, growing R&D spending, and increasing company activities, the market is anticipated to grow over the forecast period. However, the product recalls of advanced drug delivery and the challenges in nanomedicine-based drug delivery are likely to impede market growth over the forecast period.
North America Advanced Drug Delivery Systems Market Trends
The Inhalation/Pulmonary Drug Delivery System Segment is Expected to Witness Significant Growth Over the Forecast Period
The pulmonary drug delivery system is an advanced pharmaceutical technology that utilizes the lungs as the primary route of administration to efficiently deliver therapeutic agents to the body, offering improved bioavailability, targeted treatment, and enhanced patient convenience. Factors such as the increased burden of pulmonary disorders such as asthma and chronic obstructive pulmonary disease (COPD), coupled with several advantages associated with the pulmonary drug delivery system compared to conventional treatments, are projected to accelerate segmental expansion over the forecast period.
The alarming burden of respiratory disorders is likely to fuel the demand for novel drug delivery systems, boosting segmental expansion over the forecast period. For instance, according to July 2024 updated data of the Asthma and Allergy Foundation of America, over 27 million people had asthma in the United States, equivalent to around 1 in 12 people.
As per the same source, around 22 million adults aged above 18 had asthma. Thus, such a significant burden of respiratory conditions in the region is anticipated to propel the uptake of respiratory therapeutics, which is expected to boost segmental growth over the forecast period.
The higher utilization of inhalation-based drug delivery systems in respiratory conditions is further expected to fuel segmental growth. For instance, according to an article published by Health Science Reports in April 2024, lung ailments like chronic obstructive lung disease and cystic fibrosis were treated with the adoption of devices like pressurized metered‐dose inhalers, metered‐dose inhalers amid their higher pressure and greater drug deposition at target site capabilities. Thus, such benefits offered by pulmonary delivery system products are anticipated to foster segment expansion over the forecast period.
The segment’s growth is expected to be driven by the increasing volume of organic and inorganic developments undertaken by market players to introduce technologically advanced pulmonary inhalation systems in the region. For instance, in August 2023, Lupin Pharmaceuticals Inc. launched Tiotropium Bromide Inhalation Powder for the management of chronic obstructive pulmonary disease (COPD) in the United States. Thus, such new product launches are likely to propel the uptake of pulmonary drug delivery systems, which is expected to boost market growth over the forecast period.
Thus, the above-mentioned factors, including the increasing burden of pulmonary disorders such as asthma and chronic obstructive pulmonary disease (COPD) and several advantages associated with the pulmonary drug delivery system compared to conventional treatments, are expected to accelerate segmental growth over the coming years.
Understand The Key Trends Shaping This Market
Download PDF
The United States is Expected to Hold a Significant Market Share Over the Forecast Period
The United States is expected to hold a significant share of the market over the forecast period owing to factors such as the better adoption of improved drug delivery solutions and follow-up of advanced treatment approaches in healthcare. In addition, the growing inclination toward self-administration of drugs, increasing innovations in injectable drug delivery systems, the high adoption rate of new healthcare technologies, and the high prevalence of chronic diseases are also expected to boost market growth over the forecast period.
The growing burden of target diseases such as cancer, neurological diseases, cardiovascular diseases, and others is expected to increase the demand for effective and advanced drug delivery systems. For instance, according to the American Cancer Society, the estimated number of new cancer cases increased from 1.9 million in 2023 to 2.0 million in 2024. The most common type of cancers diagnosed in 2023 were breast, lung, and hematological malignancies.
According to the updated data from the Centers for Disease Control and Prevention (CDC) in May 2024, chronic kidney disease (CKD) was a significant burden in the United States, and around 35.5 million people, or 14% of the population, had CKD in the country. Thus, the increasing disease burden in the country is expected to spur the demand for nanocarriers and microparticle-based drug delivery systems for improved therapeutic outcomes.
The improved role of carrier-based systems in cancer drug delivery is further expected to foster the development of a carrier-based drug delivery system, boosting market growth over the forecast period. For instance, according to an article published by the International Journal of Molecular Sciences in April 2023, liposome-based drug delivery is ideal for treating several advanced-stage cancers like breast cancer and prostate cancer. The liposome carrier system showed improved stability and biodistribution of therapeutic agents to accelerate treatment outcomes and reduce cellular toxicity.
Such benefits from carrier-based delivery systems in cancer therapeutics are likely to foster their adoption in drug formulations, which is expected to boost the market’s growth over the forecast period.
Technological advancements and growing introductions of technologically advanced injector systems are other factors projected to accelerate the country’s market growth. For instance, in February 2024, Coherus BioSciences Inc. launched the UDENYCA on-body injector (OBI) with the LTS Sorrel wearable technology system in the United States. The newly launched product improved performance and patient convenience in wearable injection devices. Such novel technology introductions are likely to boost the market’s growth over the forecast period.
Therefore, owing to the aforementioned factors, such as the high burden of cancer and kidney disease and growing company activities, the market is anticipated to grow over the forecast period.
Get Analysis on Important Geographic Markets
Download PDF
North America Advanced Drug Delivery Systems Industry Overview
The North American advanced drug delivery systems market is semi-consolidated. Due to the continuous technological advancements in the drug delivery system, there is a possibility for newer players to enter the market in the coming years. Some of the key players in the market include 3M, Bayer, Pfizer Inc., AstraZeneca, and West Pharmaceutical Services Inc.
North America Advanced Drug Delivery Systems Market Leaders
-
3M
-
West Pharmaceutical Services, Inc.
-
Pfizer Inc.
-
Starton Therapeutics Inc
-
AstraZeneca
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competitors?
Download PDF
North America Advanced Drug Delivery Systems Market News
- January 2024: Starton Therapeutics Inc. launched Starsilon, an advanced transdermal patch delivery platform in the United States. The newly launched platform can deliver a large number of active pharmaceutical ingredients with transdermal routes.
- January 2023: The US FDA approved Airsupra (albuterol and budesonide) inhalation aerosol for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma attacks in patients with asthma 18 years of age and older.
North America Advanced Drug Delivery Systems Industry Segmentation
As per the scope of the report, advanced drug delivery systems are improved methods for delivering the drug molecule to the targeted site in a more controlled manner. These methods improve the efficacy ratio of the currently available drugs. Delivering drugs at a controlled rate, slow and targeted delivery for onsite drug release and absorption is the basis for developing advanced drug delivery systems.
North America's advanced drug delivery systems market is segmented by type, application, technology, and geography. Based on type, the market is segmented into oral drug delivery system, injection-based drug delivery system, inhalation/pulmonary drug delivery system, transdermal drug delivery system, transmucosal drug delivery system, carrier-based drug delivery system, and other types. Based on application, the market is segmented into cardiovascular diseases, oncology, urology, diabetes, CNS, ophthalmology, inflammatory diseases, infections, and other applications. Based on technology, the market is segmented into prodrug, implants and intrauterine devices, targeted drug delivery, polymeric drug delivery, and other technologies. By geography, the market is segmented into the United States, Canada, and Mexico.
| Type | Oral Drug Delivery System |
| Injection-based Drug Delivery System | |
| Inhalation/Pulmonary Drug Delivery System | |
| Transdermal Drug Delivery System | |
| Transmucosal Drug Delivery System | |
| Carrier-based Drug Delivery System | |
| Other Types | |
| Application | Cardiovascular Diseases |
| Oncology | |
| Urology | |
| Diabetes | |
| CNS | |
| Ophthalmology | |
| Inflammatory Diseases | |
| Infections | |
| Other Applications | |
| Technology | Prodrug |
| Implants and Intrauterine Devices | |
| Targeted Drug Delivery | |
| Polymeric Drug Delivery | |
| Other Technologies | |
| Geography | United States |
| Canada | |
| Mexico |
Need A Different Region or Segment?
Customize Now
North America Advanced Drug Delivery Systems Market Research FAQs
How big is the North America Advanced Drug Delivery Systems Market?
The North America Advanced Drug Delivery Systems Market size is expected to reach USD 98.64 billion in 2025 and grow at a CAGR of 4.80% to reach USD 124.70 billion by 2030.
What is the current North America Advanced Drug Delivery Systems Market size?
In 2025, the North America Advanced Drug Delivery Systems Market size is expected to reach USD 98.64 billion.
Who are the key players in North America Advanced Drug Delivery Systems Market?
3M, West Pharmaceutical Services, Inc., Pfizer Inc., Starton Therapeutics Inc and AstraZeneca are the major companies operating in the North America Advanced Drug Delivery Systems Market.
Which is the fastest growing region in North America Advanced Drug Delivery Systems Market?
North America is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in North America Advanced Drug Delivery Systems Market?
In 2025, the North America accounts for the largest market share in North America Advanced Drug Delivery Systems Market.
What years does this North America Advanced Drug Delivery Systems Market cover, and what was the market size in 2024?
In 2024, the North America Advanced Drug Delivery Systems Market size was estimated at USD 93.91 billion. The report covers the North America Advanced Drug Delivery Systems Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the North America Advanced Drug Delivery Systems Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
North America Advanced Drug Delivery Systems Industry Report
Statistics for the 2025 North America Advanced Drug Delivery Systems market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. North America Advanced Drug Delivery Systems analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
